MATERIALS AND METHODS
37. 5, 39.8, 45.6, 69.7, 78.6, 109.3, 115.7, 118.1, 119.2, 119.6, 120.6, 137.6, 150.6, 151.7, 152.6, 153.9, 154.3, 154.8, 160.7, 161.2; MS (ESI) : m/z 475 [M+H] + , 497 ; [M+Na] + ; Anal. Calcd (%) for C 25 H 26 N 6 O 4 : C, 63.28; H, 5.52; N, 17.71. Found: C, 63.17; H, 5.47; N, 17.86 .
4-Methyl-6-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4b)
White crystals (68%), m.p.184-186°C (ethyl acetate); IR (KBr): 3014, 2912, 2846, 1723, 1632, 1567 , 1508 cm -1 ; 1 H-NMR (CDCl 3 , 300 MHz) δ 2.40 (s, 3H), 3.01 (dd, 1H, J 1 =7.2 Hz, J 2 =17.9 Hz), 3.14 (dd, 1H, J 1 =11.3 Hz, J 2 =17.9 Hz), 3.77-3.87 (m, 4H), 4.08 (d, 2H, J=4.4 Hz), 4H), 1H) , 5.20 (s, 2H) , 6.29 (s, 1H), 2H), 7.24 (d, 1H, J=8.9 Hz), 7.82 (s, 1H), 8.36 (s, 1H) ; 13 C-NMR (CDCl 3 , 75 MHz) δ 18. 7, 37.7, 43.5, 46.4, 67.0, 69.6, 79.5, 109.3, 115.8, 118.1, 119.3, 119.6, 120.6, 138.8, 148.5, 150.8, 151.8, 154.0, 154.8, 155.9, 160.7, 161.4; MS (ESI) : m/z 477 [M+H] + ; Anal. Calcd (%) for C 24 H 24 N 6 O 5 : C, 60.50; H, 5.08; N, 17.64. Found: C, 60.62; H, 5.19; N, 17 .49.
54-Methyl-7-({3-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4c)
White crystals (66%), m.p.186-187°C (ethyl acetate); IR (Nujol): 3060, 1720, 1590, 1545 cm -1 ; 1 H-NMR (CDCl 3 , 112.8, 114.2, 120.1, 124.9, 125.7, 138.0, 150.2, 152.4, 152.6, 154.3, 155.1, 161.1, 161 5.52; N, 17.71. Found: C, 63.34; H, 5.46; N, 17.63 .
4-Methyl-7-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4d)
White crystals (71%), m.p. 194-196°C (ethyl acetate) ; IR (KBr): 3067, 2946, 1723, 1634, 1592 cm -1 ; 1 H-NMR (CDCl 3 , 300 MHz) δ 2.38 (s, 3H), 2.97 (dd, 1H, J 1 =7. 6 Hz, J 2 =17.8 Hz), 3.12 (dd, 1H, J 1 =11. 6 Hz, J 2 =17.8 Hz), 4H), 4.08 (d, 2H, J=4.4 Hz), 4H), 1H) , 5.16 (s, 2H) , 6.13 (s, 1H), 2H), 7.47 (d, 1H, J=8.5 Hz) , 7.80 (s, 1H), 8.36 (s, 1H) ; 13 C-NMR (CDCl 3 , 75 MHz) δ 18. 6, 37.8, 40.8, 46.7, 67.0, 69.1, 79.3, 102.2, 112.3, 112.6, 114.4, 119.6, 122.2, 125.7, 139.1, 149.8, 152.3, 153.9, 155.3, 157.1, 161.0, 161.3; MS (ESI) : m/z 477 [M+H] + ; Anal. Calcd (%) for C 24 H 24 N 6 O 5 : C, 60.50; H, 5.08; N, 17.64. Found: C, 60.64; H, 4.94; N, 17 .69.
4-Methyl-7-({3-[(6-pyrrolidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4e)
White crystals (69%), m. 6, 31.8, 39.8, 41.8, 47.9, 48.9, 69.0, 78.9, 101.9, 112.3, 112.5, 114.3, 119.9, 125.6, 126.0, 138.5, 150.0, 152.2, 152.7, 154 5.25; N, 18.25. Found: C, 62.73; H, 5.14; N, 18.16 . 7, 26.1, 37.6, 39.8, 45.5, 69.3, 78.1, 90.9, 115.1, 116.8, 119.4, 122.8, 124.1, 132.6, 137.5, 150.4, 152.6, 153.2, 153.6, 154.3, 162.5, 165.0 , 5.25; N, 18.25. Found: C, 62.81; H, 5.32; N, 18 .09. 7, 39.8, 45.8, 67.1, 69.4, 78.3, 91.2, 115.3, 116.9, 119.8, 122.8, 124.1, 132.7, 138.1, 150.9, 152.7, 153.4, 154.0, 154.1, 162.3, 164.5 7, 24.6, 26.2, 29.3, 39.7, 42.6, 46.4, 63.8, 78.9, 101.9, 112.4, 113.7, 114.3, 119.7, 124.3, 137.8, 149.8, 151.8, 152.2, 153.7, 154.1, 154.8, 161.0, 161.9 6, 29.3, 36.5, 40.7, 45.7, 64.7, 67.1, 78.5, 101.8, 112.2, 113.9, 116.2, 119.8, 125.6, 138.1, 150.9, 152.3, 152.8, 154.1, 154.4, 155.3, 161.1, 161.6 7, 29.8, 31.2, 39.8, 41.4, 47.6, 48.6, 64.2, 78.1, 101.6, 112.8, 113.2, 113.8, 120.1, 124.8, 126.0, 138.4, 150.6, 151.3, 151.8, 154.7, 155.2, 160.8, 161.3 A solution of oxime 2a (62 mg, 0.24 mmol) in methanol (2 ml) was added dropwise during 1.5 h at r.t. in a mixture of acrylate 3e (60 mg, 0.26 mmol), PIDA (84 mg, 0.26 mmol) and TFA (4 μl, 5.7 mg, 0.05 mmol) in methanol (3 ml). The mixture was stirred for 4 h at r.t.. Then, the solvent was evaporated and the residue was separated by column chromatography [hexane/ethyl acetate (2:1)] to give the aldehyde 1a (10 mg, 17%) followed by the isoxazoline 4k, 83 mg (71% yield). This reaction between the oxime 2a and acrylate 3e in the presence of NCS and Et 3 N gave the isoxazoline 4k (34% yield) along with the furoxan 5a (27%). 7, 24.5, 26.1, 39.4, 39.8, 46.6, 78.2, 116.0, 117.0, 118.2, 119.3, 120.7, 124.7, 137.8, 146.0, 149.1, 150.7, 151.3, 151.5, 153.3, 154.1, 160.1, 167.9 7, 39.5, 40.7, 46.7, 67.0, 78.5, 116.1, 117.0, 118.3, 119.6, 120.9, 124.7, 138.9, 146.2, 149.5, 150.0, 151.4, 151.6, 153.1, 153.9, 160.1, 167.9 8, 31.9, 39.0, 42.5, 47.4, 78.6, 115.8, 117.5, 117.8, 119.8, 120.2, 124.5, 138.1, 145.8, 149.4, 150.2, 151.0, 151.4, 153.6, 154.5, 160.3, 167.8 
4-({3-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4f)
White
4-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (4g)

4-Methyl
2-Oxo-2H-chromen-6-yl 3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazole-5-carboxylate (4o)
White crystals (67%) 
General Procedure for the Synthesis of Acetals 7a-d. Synthesis of 6-(2,2-diethoxyethoxy)-4-methyl-2H-chromene-2-one (7a).
Anhydrous K 2 CO 3 (0.4 g, 2.84 mmol) was added to the solution of hydroxycoumarin 6a (0.5 g, 2.84 mmol) in DMF (10 ml) followed by 2-bromo-1,1-diethoxyethane (0.42 ml, 0.559 g, 2.84 mmol). The resulted mixture was heated at 90°C for 24 h, filtered while hot and the solid was washed with DCM. The filtrate was evaporated and the residue was separated by column chromatography [hexane/ethyl acetate (3:1)] to give compound 7a, 0.711 g (86% yield). 3, 18.6, 62.8, 69.5, 100.6, 108.9, 115.5, 117.9, 119.4, 120.5, 148.2, 151.8, 155.1, 160.8 5, 63.0, 69.6, 100.7, 111.5, 117.2, 117.9, 119.4, 120.3, 143.4, 148.8, 155.4, 160.9 6, 73.7, 109.5, 116.1, 118.5, 119.1, 120.9, 148.9, 151.5, 154.3, 160.5, 197.9 6, 65.8, 108.7, 115.9, 118.3, 119.3, 120.7, 146.9, 148.6, 151.8, 154.6, 160.9 8, 111.8, 117.5, 118.2, 119.4, 120.7, 142.9, 146.9, 149.1, 154.6, 160.8 6, 65.6, 102.2, 112.5, 112.7, 114.3, 125.7, 146.6, 148.7, 152.3, 155.3 6, 112.1, 112.8, 113.3, 128.9, 143.4, 144.8, 148.5, 153.4, 161.0 
6-(2,2-Diethoxyethoxy)-4-methyl-2H-chromene-2-one (7a)
General Procedure. 1,3-Dipolar Cycloaddition Reactions of (Coumarinyl)Acetaldehyde Oximes with 9-allylpurines. Synthesis of 4-methyl-6-({5-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-2H-chromen-2-one (11a).
In the solution of oxime 9a (37 mg, 0.16 mmol) in dry DMF (5 ml) NCS (32 mg, 0.22 mmol) was added under stirring in portions during 1 h. The resulted mixture was stirred for 30 min. The allylpurine 10a (39 mg, 0.16 mmol) and Et 3 N (0.03 ml, 16 mg, 0.16 mmol) were then added and the mixture was stirred at r.t. for 24 h under N 2 atmosphere. The mixture was filtered, the solid was washed with DCM and the filtrate was evaporated. The residue was chromatographed in a column [hexane/ethyl acetate (2:1)] and gave after the elution of starting purine 10a (5 mg, 13%) the isoxazoline 11a, 53 mg, (70% yield). 
4-Methyl-6-({5-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-2H-chromen-2-one (11a)
6-({5-[(6-Chloro-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-4-methyl-2H-chromen-2-one (11b)
White crystals (67%), m. MHz) δ 18. 6, 37.9, 46.7, 62.9, 78.4, 108.6, 115.9, 118.3, 118.9, 120.6, 131.2, 146.1, 148.6, 151.4, 151.7, 152.0, 153.8, 155.4, 160.6, 161.9 -[(6-piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy) 7, 24.8, 26.2, 37.7, 46.0, 46.6, 62.9, 79.0, 102.0, 112.0, 112.7, 114.5, 119.4, 125.8, 138.8, 150.8, 152.3, 152.5, 153.9, 154.9, 155.1, 160.5, 161.0 
6-({5-[(6-Piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-2H-chromen-2-one (11c)
4-Methyl-7-({5
7-({5-[(6-Chloro-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-4-methyl-2H-chromen-2-one (11e)
White crystals (68%) 7, 37.9, 46.7, 66.4, 78.3, 102.1, 111.9, 112.9, 114.7, 118.7, 125.9, 131.3, 146.1, 151.4, 152.0, 152.2, 155.0, 155.2, 160.3, 160.8 
4-Methyl-7-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-5-yl}methoxy)-2H-chromen-2-one (11f)
White crystals (65%), m. 6, 37.7, 45.9, 46.2, 62.9, 67.0, 78.9, 102.1, 112.0, 112.7, 114.5, 119.6, 125.8, 139.6, 150.8, 152.0, 152.2, 153.8, 154.9, 155.0, 160.4, 160.9; MS (ESI) : m/z 477 [M+H] + ; Anal. Calcd (%) for C 24 H 24 N 6 O 5 : C, 60.50; H, 5.08; N, 17.64. Found: C, 60.58; H, 5. 14; N, 17.55.
7-({5-[(6-Piperidin-1-yl-9H-purin-9-yl)methyl]-4,5-dihydroisoxazol-3-yl}methoxy)-2H-chromen-2-one (11g)
White crystals (62%) 7, 26.2, 37.7, 46.2, 46.8, 63.0, 79.1, 102.1, 112.4, 113.5, 114.0, 119.3, 129.0, 139.0, 143.7, 149.9, 152.0, 152.5, 153.1, 154.8, 155.0, 160.7, 161.4 , 5.25; N, 18.25. Found: C, 62.71; H, 5.20; N, 18 .16.
General Procedure. 1,3-Dipolar Cycloaddition Reactions of (purin-9-yl)Acetaldehyde Oximes with Propargyloxycoumarins. Synthesis of 4-methyl-6-({3-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13a)
TFA (4 μl, 5.7 mg, 0.05 mmol) was added to the solution of propargyloxycoumarin 12a (56 mg, 0.26 mmol) and PIDA (84 mg, 0.26 mmol) in methanol (3 ml). Then, in the resulted mixture, a solution of oxime 2a (62 mg, 0.24 viii mmol) in methanol (2 ml) was transferred dropwise during 1.5 h and the mixture was stirred at r.t. for 4 h. The solvent was evaporated and the solid residue was separated by column chromatography [hexane/ethyl acetate (2:1)] followed by PTLC (ethyl acetate) to give the aldehyde 1a (5 mg, 9%) and the isoxazole 13a (73 mg, 64%), while the furoxan 5a (20 mg, 16%) [18] eluted next.
When the reaction of 2a and 12a was performed according to the general procedure 5.1.3., the isoxazole 13a (28%), the furoxan 5a (25%) and the starting oxime 2a (45%) were isolated from the reaction mixture. -6-({3-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13a 6, 26.2, 29.7, 38.9, 47.2, 62.1, 103.4, 109.8, 116.0, 118.3, 119.3, 119.6, 120.8, 138.1, 148.9, 150.1, 151.5, 152.2, 154.0, 159.6, 160.5, 160.7, 168.8 6, 38.6, 45.9, 62.0, 67.0, 103.2, 109.7, 115.9, 118.3, 119.2, 120.7, 138.3, 148.8, 150.7, 151.5, 152.4, 153.9, 154.0, 158.9, 159.6, 160.5, 168.7 
4-Methyl
4-Methyl-6-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13b)
3,4-bis-[(6-Morpholin-4-yl-9H-purin-9-yl)methyl]-1,2,5-oxadiazole-2-oxide (5b)
White crystals (18%), m. 
4-Methyl-7-({3-[(6-piperidin-1-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13c)
White crystals (57%), m.p.165-167°C (DCM); IR (Nujol): 3035, 1710, 1620, 1560 cm -1 ; 1 H-NMR (CDCl 3 , 300
MHz) δ 1.65-1.79 (m, 6H), 2.38 (s, 3H), 4.19-4.31 (m, 4H), 5.15 (s, 2H), 5.44 (s, 2H), 6.16 (s, 1H), 6.40 (s, 1H), 2H), 7.50 (d, 1H, J=8.5 Hz), 7.79 (s, 1H), 8.36 (s, 1H) ; 75 MHz) δ 18.8, 26.2, 29.7, 38.9, 47.7, 61.2, 101.9, 103.5, 112.5, 112.8, 114.7, 119.3, 126.0, 128.9, 129.8, 138.5, 151.4, 152.4, 155.1, 159.3, 160.3, 161.0, 168.3 , 5.12; N, 17.79. Found: C, 63.62; H, 5.04; N, 17.68 .
4-Methyl-7-({3-[(6-morpholin-4-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13d)
White crystals (54%), m. 4, 38.6, 45.9, 61.2, 66.9, 102.0, 103.3, 112.5, 114.6, 119.7, 125.9, 138.7, 150.4, 151.8, 152.7, 153.1, 153.6, 155.0, 159.5, 160.5, 161.3, 168 H, 4.67; N, 17.71. Found: C, 60.83; H, 4.62; N. 17 .65.
7-({3-[(6-Piperidin-1-yl-9H-purin-9-yl)methyl]isoxazol-5-yl}methoxy)-2H-chromen-2-one (13e)
White crystals (56%), m. 26.2, 38.7, 46.9, 61.4, 102.1, 103.5, 112.7, 113.6, 114.1, 119.6, 129.1, 138.6, 143.0, 150.4, 152.1, 153.3, 155.8, 159.6, 160.6, 161.2, 168 7, 45.8, 61.3, 67.0, 101.9, 103.4, 112.7, 113.5, 114.1, 119.1, 129.1, 138.3, 143.2, 150.6, 152.3, 153.2, 155.7, 159.5, 160.5, 160.8, 168 9, 38.6, 47.9, 61.4, 102.2, 103.4, 112.7, 113.7, 114.2, 120.1, 129.1, 138.6, 143.0, 150.1, 152.4, 152.7, 155.8, 159.8, 160.6, 161.9, 168.1; MS (ESI) 5, 26.2, 39.0, 47.6, 61.4, 91.6, 104.3, 115.2 116.9, 119.6, 123.1, 124.2, 132.9, 138.4, 150.8, 152.4, 153.5, 154.1, 159.6, 162.0, 164.5, 166.5 7, 46.0, 61.3, 67.0, 91.5, 104.5, 115.1, 116.8, 116.9, 123.0, 124.2, 132.9, 138.4, 150.5, 152.1, 153.5, 153.7, 159.7, 162.0, 164.5, 166.4 General Procedure for the Synthesis of 9-propargylpurines 14a-c. Synthesis of 6-piperidin-1-yl-9-prop-2-yn-1-yl-9H-purine (14a)
Anhydrous K 2 CO 3 (0.297 g, 2.1 mmol) was added to the solution of 6-piperidin-1-yl-9H-purine (.43 g, 2.1 mmol) in DMF (15 ml) followed by propargyl bromide (0.16 ml, 0.25 g, 3.32 mmol). The mixture was heated at 90°C for 24 h and filtered, while hot. The solid K 2 CO 3 was washed with DCM and the filtrates were evaporated. The residue was chromatographed in a column [hexane/ethyl acetate (1:1)] to give compound 14a (0.641 g, 80%) 1, 41.5, 46.5, 74.6, 78.4, 119.8, 137.0, 150.5, 152.7, 154.0 1, 40.1, 48.0, 48.6, 74.4, 78.3, 119.9, 137.6, 149.6, 152.7, 152.9 TFA (4 μl, 5.7 mg, 0.05 mmol) was added to the solution of propargylpurine 14a (63 mg, 0.26 mmol) and PIDA (84 mg, 0.26 mmol) in methanol (3 ml). Then, in the resulted mixture, a solution of oxime 9d (53 mg, 0.24 mmol) in methanol (2 ml) was transferred dropwise during 1.5 h and the mixture was stirred at r.t. for 4 h. The solvent was evaporated and the solid residue was separated by column chromatography [hexane/ethyl acetate (2:1)] followed by PTLC (ethyl acetate) to give the aldehyde 8d (5 mg, 11%) and the isoxazole 15a (62 mg, 56%), while the furoxan 16 (20 mg, 19%) eluted next. 7, 26.2, 38.7, 47.0, 62.0, 102.3, 103.1, 112.7, 113.5, 114.0, 119.6, 129.1, 137.8, 143.1, 149.7, 151.7, 153.4, 155.9, 160.4, 160.7, 161.0, 166.8 6, 102.4, 102.5, 111.5, 112.1, 112.3, 114.0, 114.1, 114.7, 114.9, 129.3, 129.4, 142.4, 142.9, 153.8, 155.8, 155.9, 160.0, 160.2, 160.4, 160.7; MS (ESI) : m/z 435 [M+H] + ; Anal. Calcd (%) for C 24 H 14 N 2 O 8 : C, 60.83; H, 3.25; N, 6.46. Found: C, 60.95; H, 3.17; N, 6 .41. 47.0, 62.0, 66.9, 102.2, 103.8, 112.8, 113.6, 114.1, 119.0, 129.1, 139.1, 143.0, 149.6, 152.2, 153.6, 155.6, 159.9, 160.5, 160.9, 165.9 
7-({5-
[
7-({5-[(6-Morpholin-4-yl-9H-purin-9-yl)methyl]isoxazol-3-yl}methoxy)-2H-chromen-2-one (15b)
